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Abstract
Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of immature myeloid cells that exist at very low numbers in
healthy subjects but can expand significantly in malignant, infectious, and chronic inflammatory diseases. These cells are
characterized as early-MDSCs, monocytic-MDSCs, and polymorphonuclear-MDSCs and can be studied on the basis of their
immunophenotypic characteristics and their functional properties to suppress T-cell activation and proliferation. MDSCs have
emerged as important contributors to tumor expansion and chronic inflammation progression by inducing immunosuppressive
mechanisms, angiogenesis and drug resistance. Most experimental and clinical studies concerning MDSCs have been mainly
focused on solid tumors. In recent years, however, the implication of MDSCs in the immune dysregulation associated with
hematologic malignancies, immune-mediated cytopenias and allogeneic hemopoietic stem cell transplantation has been
documented and the potential role of these cells as biomarkers and therapeutic targets has started to attract a particular interest
in hematology. The elucidation of the molecular and signaling pathways associated with the generation, expansion and function of
MDSCs in malignant and immune-mediated hematologic diseases and the clarification of mechanisms related to the circulation and
the crosstalk of MDSCs with malignant cells and other components of the immune system are anticipated to lead to novel therapeutic
strategies. This review summarizes all available evidence on the implication of MDSCs in hematologic diseases highlighting the
challenges and perspectives arising from this novel field of research.
Introduction
References to cells of myeloid origin that promote tumor
progression through immune evasion mechanisms while also
induce inflammatory and hemopoietic responses, go back to the
1970s.1 Thesemyeloid cells display immunosuppressive properties
and expand particularly in neoplastic, infectious, and inflamma-
tory diseases; they were initially characterized as natural
suppressor or veto or null cells because of the absence of surface
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markers of T-cells, B-cells, natural killer (NK) cells ormacrophages
and later as immature myeloid cells ormyeloid suppressor cells to
denote their main biologic properties.1 In 2007, the term myeloid
derived suppressor cells (MDSCs) was introduced as the best to
reflect the origin and functional trait of these cells despite the
heterogeneity in their phenotypic, genomic and biochemical
characteristics.2 In recent years, MDSCs have been recognized
as important immune regulators, potential biomarkers and even
therapeutic targets in cancer and other diseases associated with
chronic inflammation including infectious diseases, autoimmune
diseases and trauma, among others.3,4
In humans, MDSCs are identified as CD11b+CD33+HLA-
DR/low cells.5 They can be further divided into 2 distinct
populations with the main difference being the expression of
CD14 (monocytic—MDSCs, M-MDSCs) or CD15 (polymor-
phonuclear—MDSCs, PMN-MDSCs) surface molecules. M-
MDSCs are morphologically identical to conventional mono-
cytes from which they can be distinguished on the basis of
HLA-DR expression. PMN-MDSCs can be distinguished from
conventional PMN based on their low-density properties
following centrifugation over density gradient as well as on
the expression of the lectin type oxidized LDL receptor 1
(LOX-1).3,6 A third, minor population of MDSCs has been
recognized, the early-stage MDSCs (e-MDSCs), which express
neither CD15 nor CD14; these cells are characterized as Lin
(CD3, CD14, CD15, CD19, CD56)HLA-DRCD33+ and
comprise immature progenitor and precursor cells with
myeloid colony-forming activity.5 In mice, MDSCs are
characterized by the expression of Gr1 and CD11b and can
also be divided into PMN-MDSCs (CD11b+Ly6G+Ly6Clow
cells), M-MDSCs (CD11b+Ly6GLy6Chigh), and non-PMN-
MDSCs/non-M-MDSCs (CD11b+Ly6GmedLy6Cmed cells).5,7
Notably, the term granulocytic-MDSCs (G-MDSCs) has
previously been used for the definition of PMN-MDSCs in
both human and mice.
The precise mechanisms underlying the generation of
MDSCs remain largely unknown. MDSCs are likely to arise
under inflammatory conditions when there is an increased
demand for myeloid cells (emergency myelopoiesis); they then
expand as immature cells in the bone marrow (BM) or even
extramedullary (mainly in the spleen) and migrate into the
peripheral blood (PB) where their terminal differentiation is
blocked finally transforming into functionally active MDSCs.
According to this model, 2 signals are required for MDSCs’
generation; the expansion/mobilization signal mediated mainly
through growth factors such as granulocyte and granulocyte/
monocyte colony stimulating factors (G-CSF and GM-CSF,
respectively) and proinflammatory mediators such as interleu-
kin-6 (IL-6) and prostaglandin E2 (PGE2) resulting in
upregulation of the signal transducer and activator of
transcription (STAT)-3 in myeloid progenitor cells; and the
activation signal mediated through proinflammatory stimuli
such as lipopolysaccharides (LPS), PGE2, IL-1 and S100A8/A9
resulting in NF-kB upregulation and induction of the suppres-
sive MDSC phenotype. Recent evidence suggests that M-
MDSCs may also arise by reprogramming of monocytes
through pathogen- or danger-associated molecular patterns
(PAMPs or DAMPs, respectively) and Toll-like receptor (TLR)
activation as well as through certain cytokines and mediators
such as IL-10, Wnt5a, and PGE2.8 Another hypothesis,
although still controversial, indicates that PMN-MDSCs may
represent an activation stage of PMNs derived from immature
or mature granulocytes8 (Fig. 1).
The fundamental functional characteristic of MDSCs is the
capacity to suppress immune cells, predominantly T-cells and
to a lesser degree B-cells and NK-cells.1,3,9 Main transcription
factors involved in the suppressive function of MDSCs include
STAT3, hypoxia inducible factor 1a (HIF-1a) and CCAAT/
enhancer binding protein b (C/EBPb).1,3,9 Effector molecules
produced by MDSCs include arginase-1, which induces L-
arginine deprivation and causes nitrosylation and down-
regulation of the CD3z part of the T-cell receptor complex;
cyclooxygenase (COX)-2 and indoleamine 2,3-dioxygenase
(IDO); inducible nitric oxide synthase (iNOS), which leads to
the production of NO, induction of T-cell apoptosis and
suppression of T-cell proliferation; NADPH oxidase 2 (NOX2),
which inhibits the proliferation of T-cells through production
of reactive oxygen species (ROS) and nitration of CD3z and
major histocompatibility complex (MHC)-I; heme oxygenase 1
(HO-1) which also inhibits T-cell proliferation through carbon
monoxide (CO) production; mediators reducing cysteine
provision to T-cells by antigen presenting cells; membrane-
bound transforming growth factor b1 (TGFb1), which
promotes the anergy of NK-cells and the development of
regulatory T cells (Treg); IL-10, which leads to Th2 deviation
and type 2 polarization of macrophages; and ADAM metal-
lopeptidase domain 17 (ADAM17) which cleaves L-selectin
(CD62L) from T-cells leading to their homing in lymph nodes
and sites of inflammation.1,3,9 In addition to their immune-
suppressive properties, MDSCs promote tumor progression
and metastasis by affecting the remodeling of the tumor
microenvironment and tumor angiogenesis via production of
vascular endothelial growth factor (VEGF), basic fibroblast
growth factor (bFGF), and matrix metalloproteinase-9
(MMP9).1,3,9
The immune system displays a prominent role in the
pathogenesis, pathophysiology and response to treatment of
patients with hematologic malignancies, BM failure syndromes
and autoimmune disorders10,11; therefore, immune modulating
agents (i.e., lenalidomide, monoclonal antibodies, hypomethylat-
ing drugs, signal transduction inhibitors among others) have
significantly improved the outcome of these patients.10,11 As
expected, the possible implication of MDSCs in the immune
dysregulation associated with these disease entities and their
potential role as biomarkers and therapeutic targets has started to
attract a particular interest in hematology.10,11 This is further
triggered by the fact that MDSCs in addition to their
immunosuppressive properties on T-cells can also interact with
the mesenchymal stromal cells (MSCs) in the BM through shared
molecules and mechanisms and this interplay may alter the
immunoregulatory properties of the BM microenvironment and
consequently, the disease pathophysiology and response to
treatment.12 This review summarizes all available evidence on the
implication ofMDSCs in hematologic malignancies and immune-
mediated BM failure syndromes and cytopenias highlighting the
challenges and perspectives arising from this novel field of
research.
Myeloproliferative neoplasms and acute
leukemia
Myeloproliferative neoplasms (MPNs) are a group of hemopoi-
etic stem cell disorders characterized by clonal proliferation of
myeloid-lineage cells and chronic inflammation.13 Classic MPNs
include chronic myeloid leukemia (CML), polycythemia vera
(PV), essential thrombocythemia (ET), and primarymyelofibrosis
Bizymi et al. Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets
2
(PMF). Studies on MDSCs in CML have demonstrated increased
frequency of PMN-MDSC subsets in Sokal high-risk patients,
expressing high levels of programmed death receptor ligand-1/
programmed death receptor-1 (PD-L1/PD-1) and arginase-1.14,15
Increased PMN-MDSC and M-MDSC subsets in CML patients
at diagnosis have been shown to return to normal levels after
treatment with the tyrosine kinase inhibitor (TKI) imatinib and
M-MDSCs frequency has been proposed as a prognostic factor in
CML patients receiving the TKI dasatinib.16 Overall, CML
patients appropriately responding to TKI therapies (imatinib,
nilotinib, dasatinib), parallel to the reduction of abl-bcr
transcripts display a decrease in M-MDSC frequency and
immunosuppressive activity and restoration of T-cell and NK-
cell immune functions.17 Recent evidence also suggests that
MDSCs may have a critical role in CML malignant cell immune
escape. In particular, it has been shown that the malignant cell
expansion in CML is maintained by a small subset of CD34+/
CD38 leukemic stem cells that may escape immune cell
surveillance within immunosuppressive BM niches consisting
of populations of MSCs and PMN-MDSCs with T-cell suppres-
sive capacity.18 It is therefore reasonable to hypothesize that
targeting of MDSCs in CML may restore the T-cell mediated
leukemia surveillance and improve further patients’ long-term
outcome.
As regards to the Philadelphia negative MPNs, namely PV, ET,
and PMF, a number of studies have documented abnormal
reserves and function of immune cells including increase of
monocyte/macrophages, altered regulatory T-cell frequency, NK-
cell dysfunction, and expansion of MDSCs.19 Recent evidence
also suggests that although MDSCs are significantly elevated in
MPNs, no differences can be identified in their frequency among
different MPN categories and no correlations with JAK2 allele
Figure 1. Proposed signals for MDSC generation. In humans, MDSCs are identified as CD11b+CD33+HLA-DR/low cells and are classified by the
expression of CD14 as monocytic-MDSCs (M-MDSCs) or CD15 as polymorphonuclear-MDSCs (PMN-MDSCs). A minor population of MDSCs, the early stage
MDSCs (e-MDSCs), expressesneitherCD15norCD14.The fundamental functional characteristic ofMDSCs is thecapacity to suppress immunecells, predominantlyT-
cells and to a lesser degree B-cells and NK-cells. MDSCs arise under inflammatory conditions due to an increased demand formyeloid cells (emergencymyelopoiesis);
they expand from the hematopoietic stemcell (HSC) as immature cells in the bonemarrow (BM) or extramedullary, andmigrate into the peripheral blood (PB)where their
terminal differentiation is blocked transforming into functionally active MDSCs. Two types of signals are required for MDSCs’ generation: the expansion/mobilization
signal through growth factors such as granulocyte and granulocyte/monocyte colony stimulating factors (G-CSF and GM-CSF, respectively) and proinflammatory
mediators such as interleukin-6 (IL-6) and prostaglandin E2 (PGE2) resulting in upregulation of STAT3 in myeloid progenitor cells; and the activation signal mediated
through proinflammatory stimuli such as lipopolysaccharides (LPS), PGE2, IL-1, and S100A8/A9 resulting in NF-kB upregulation and induction of the suppressive
MDSC phenotype. M-MDSCs may also arise by reprogramming of monocytes through pathogen- or danger-associated molecular patterns (PAMPs or DAMPs,
respectively) and Toll-like receptor (TLR) activation as well as through certain cytokines and mediators such as IL-10, Wnt5a, and PGE2. PMN-MDSCs may also
represent an activation stage of PMNs derived from immature or mature granulocytes.
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burden can be made.20 MPN-derived MDSCs have also been
shown to display significantly elevated arginase-1 mRNA and
T-cell suppressive activity.20
There are only a few studies on MDSCs in acute leukemias
clearly showing the negative impact of their presence on the
disease prognostic characteristics. A recent study has shown
variable but significantly higher number of MDSCs, defined as
CD14HLA-DRCD33+CD11b+ cells, in PB of patients with
acute myeloid leukemia (AML) compared to patients with
acute lymphoblastic leukemia (ALL) and significant correlation
of AML-MDSCs with conventional prognostic factors at
diagnosis, namely WBC count, CD34 frequency and nucleo-
phosmin (NPM1) and fms-like tyrosine kinase 3 (FLT3) gene
mutations. It has also been shown that CD33+CD11b+HLA-
DR/low MDSCs accumulate in the BM of AML patients and
their presence may have an impact on disease prognosis and
patients’ clinical course.21 Furthermore, MDSCs levels in newly
diagnosed AML patients have been reported to correlate with
AML subtype, presence of chromosomal abnormalities and
gene alterations, extramedullary involvement, and plasma D-
dimer levels. After the induction therapy, MDSCs significantly
decrease in patients with complete remission but not in patients
with partial or no response while on follow-up and MDSCs’
frequency correlate with minimal residual disease (MRD) levels
and Wilms 1 (WT-1) gene detection.21 Another study has
shown expansion of MDSCs from PB mononuclear cells
(PBMCs) following contact with AML cell lines or primary
AML cells via tumor-derived extracellular vesicles; it has been
postulated that the mucin 1 (MUC1) oncoprotein induces
increased expression of c-myc in extracellular vesicles that are
then taken-up by the myeloid progenitor cells resulting in
downstream effects on cell cycle proteins and selective
proliferation of MDSCs.22 As regards to ALL, it has been
shown that pediatric patients with B-cell ALL display increased
number of PMN-MDSCs in PB and BM compared to age-
matched healthy individuals and PMN-MDSC frequency
correlate with prognostic markers such as MRD and CD20+
blast cell counts as well as with response to therapy.23,24 PMN-
MDSCs from patients in remission have been reported to lose
their suppressive function corroborating the effect of these
cells in mediating immune evasion mechanisms.23,24 All these
observations and available evidence implicating MDSCs in
both AML and ALL progression and outcome highlight the
emerging role of these cells as independent biomarkers and
promising targets for the development of novel therapeutic
strategies.
Myelodysplastic syndromes
Myelodysplastic syndromes (MDS) are clonal hemopoietic stem
cell disorders characterized by PB cytopenias, dysplastic
changes in one or more BM cell lineages and increased risk
of AML.25 Allogeneic hemopoietic stem cell transplantation
(Allo-HSCT) with donor T-cell reactivity against the malignant
cells is the only curative therapy for MDS. BM microenviron-
ment in low-risk MDS is characterized by persistent inflamma-
tion and expansion of autoimmunity-associated T-helper 17
(Th17) cells whereas expansion of MDSCs and Tregs and
reduced number of Th17 characterize high-risk MDS.26,27
Lin(CD3/CD14/CD16/CD19/CD20/CD56)HLA-DRCD33+
MDSCs in high-risk MDS are capable to induce apoptosis of
erythroid precursor cells and their expansion is driven, at least
in part, by the interaction of S100A9 protein with the CD33
cell surface antigen.28 Immune phenotyping with mass
cytometry and unsupervised viSNE analysis of 35-markers
per cell of thawed MDS and AML BM samples has revealed
that one of the strongest marker signals was the expression of
S100A9. This protein is seen in multiple cell types including
MDSCs and its expression was more common in MDS without
excess of blasts. S100A9 mainly characterizes M-MDSCs and
together with its binding partner, S100A8, is included in the
DAMP molecules displaying intra- and extracellular functions
and inflammatory, antiinflammatory and immune regulatory
properties.29,30 Varying S100A9 expression resulted in differ-
ent MDSC functions, with more proinflammatory effect in low
risk and immunosuppressive effect in high-risk MDS. S100A9
and CD33 ligand/receptor pair interactions recruit components
to the immunoreceptor tyrosine-based inhibition motif (ITIM)
finally resulting in secretion of suppressive IL-10 and TGFb1.28
Work based on fresh PB and BM samples from MDS patients
confirmed the secretion of these 2 cytokines by MDSCs, but
interestingly, this secretion was higher in PMN-MDSCs than in
M-MDSCs.31 In fact, PMN-MDSC subset dominated the
MDSC-expansion in high-risk patients. The BM homing
chemokine receptors (CXCR4, CX3CR1) were expressed at
a higher level on M-MDSCs in high-risk MDS, and there was
different expression of CX3CR1 between healthy donors, low-
risk MDS and high-risk MDS patients.31
The importance of MDSCs in suppression of hemopoiesis in
MDS has been demonstrated in 2 genetically manipulated animal
models; the S100A9 transgenic mice, displaying BM accumula-
tion of MDSC and progressive cytopenia and the mDia1/
miR146-a double knockout mice, developing age-related inflam-
matory BM microenvironment and anemia.28,32 S100A8/A9
activation of MDSC is through the NF-kB signaling pathway;
therefore, we may hypothesize that by targeting this pathway we
could reduce MDSCs levels.33
Drugs widely used forMDS have lately been shown to affect T-
cell polarization, which may suggest effects on MDSCs activity.
Azacitidine, the drug of choice in high-riskMDS, has been shown
to affect T-cell polarization in the Th17/Treg-axis in high-risk
MDS and to influence levels of BM CD57+ T-cells, CD57+ T-cell
degranulation and CD34+ BM cell directed cytotoxicity.34,35
Specific MDSC-targeting in MDS has so far been aiming at
CD33-expressing cells.36 So far, BI 836858 (Fc-engineered anti-
CD33 moAb) for antibody-dependent cell-mediated cytotoxicity
by NK-cells is currently tested in MDS patients in an ongoing
Phase I/II clinical trial (ClinicalTrials.gov Identifier:
NCT02240706). Additionally, a clinical trial with CD16/IL-
15/CD33 (161533) tri-specific killer cell engager for the
treatment of CD33-expressing myeloid malignancies, including
high-risk MDS, is not yet recruiting (NCT03214666). Overall,
the implication and therapeutic targeting ofMDSCs inMDS is an
interesting, open field of research.
Lymphomas
Different mice models have been used to study MDSC biology in
lymphomas. For example, M-MDSC and PMN-MDSCs from
EL4 and EG7 lymphoma models display immunosuppressive
capacity associated with increased production of NO and
nitrotyrosine (M-MDSCs) and ROS (PMN-MDSCs).37,38 Fur-
thermore, MDSCs from A20 B-cell lymphoma model, operate as
tolerogenic antigen presenting cells capable of antigen uptake and
presentation to tumor-specific Tregs.39 In humans, the number of
circulating MDSCs has been correlated with poor prognosis in
Bizymi et al. Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets
4
diffuse large B-cell lymphoma (DLBCL),40,41 indolent lympho-
ma,42 chronic lymphocytic leukemia,43,44 and Hodgkin lympho-
ma (HL).40,45 However, only few of the suppressive mechanisms
involved in MDSC biology in these disease entities have been
elucidated.46 In DLBCLs, an increase of immunosuppressive
PMN-MDSC numbers expressing arginase-1 has been noticed,
however correlation with clinical outcome was not been
documented in all studies.40,41,47 Similarly, increased numbers
of M-MDSCs (CD14+HLA-DRlow) have been detected in PB
from DLBCL patients in various studies.41,42,48,49 M-MDSCs
from DLBCL patients have been found to overexpress genes
involved in MDSC biology such as IL4-R, IL6-R, RELB, STAT3,
NFKB, CEBPb, AIM2, TNFR2, and NOX2. Additionally, the T-
cell suppressive effect of MDSCs was mediated by a release of IL-
10 and S100A12 and an increase in PD-L1 expression.41
Increased circulating PMN-MDSC (CD66b+CD33dimHLA-
DR) numbers compared to healthy donors with elevated
arginase-1 activity has been observed in a cohort of 31 patients
with indolent lymphomas40 whereas increased M-MDSC
(CD14+HLA-DRlow) numbers have been detected in another
cohort of 22 patients with indolent lymphomas.42 Increased
PMN-MDSC and M-MDSC numbers and arginase-1 activity
have been also identified in PB of HL patients.40,45 As regards to
T-cell lymphomas, even less is known about the potential role of
MDSCs. Patients with mycosis fungoides and Sézary syndrome
with stage IB and above have been shown to display increased
production of ROS by MDSCs compared to patients with stage
IA or healthy controls, despite the normal MDSC numbers and
this abnormality was reversed following anti-CD25 denileukin
diftitox or IFN-a2b treatment.50 Collectively, all the above
studies have pointed out the possibility of targeting MDSCs in
future therapeutic trials with lymphoma patients by controlling
their expansion and/or blocking their immunosuppressive
functions.
Multiple myeloma
Multiple myeloma (MM) is a B-cell malignancy characterized by
expansion of monoclonal plasma cells preferentially in the BM
and the accumulation of monoclonal immunoglobulins in the PB.
It is nowwidely accepted that the BMmicroenvironment displays
a prominent role in pathophysiology of the disease by providing a
protective niche to the plasma cells that promotes the immune-
escape, drug-resistance, and angiogenesis.51 An interactive
crosstalk between the malignant cells and the BM microenviron-
ment is also responsible for many clinical characteristics of the
disease such as the osteolytic lesions, anemia and immunosup-
pression.51 According to recent studies, MDSCs are involved in
the pathogenesis and progression of MM.52–54 Experiments in
5T2 and 5T33MM mice models of MM have shown that the
malignant plasma cells can induce the generation and survival of
both PMN-MDSCs and M-MDSCs that accumulate in the BM
in early stages and in PB at later stages, and display T-cell
immunosuppressive activity, through production of NOS,
arginase-1 and IL-10, which is highest among M-MDSCs.55,56
In the DP42 MMmouse model, however, a more prominent role
of the BM PMN-MDSC population was demonstrated for the
induction of plasma cell growth and chemoresistance.57 The
malignant cells secrete factors such as IL-6, GM-CSF, VEGF, IL-
1b and exosomes leading to the activation of STAT3 and STAT1
pathways, increase expression of Bcl-xL and Mcl-1 proteins and
release of NO enhancing finally the BM angiogenesis as well as
the survival and suppressive activity of MDSCs.55,58,59 These
effects can be further potentiated by the MSCs in MM BM
microenvironment.60,61 Using the 5TGM1 mouse model it has
also been shown that tumor-inducedMDSCs, in addition to their
immunosuppressive effect, can be differentiated into mature and
functional osteoclasts contributing therefore to the bone
destruction associated with the disease.62 The importance of
MDSCs in the development of MM was demonstrated in the
S1009 knockout transgenic mice which display defective
response to cancer and delay in the development of MM
following inoculation of MM cells which is reversed following
adoptive transfer of MDSCs.63 In humans, early studies have
shown that MDSCs isolated from the PB of patients with MM
display a T-cell inhibitory effect which can be abrogated by drugs
inhibiting arginase-1 and iNOS activity.64 Similar to mice
models, increased number of PMN-MDSCs with immunosup-
pressive properties has been reported in the BM and PB of
patients with MM at diagnosis and relapse compared to healthy
subjects.63,65,66 The frequency of PMN-MDSCs has been shown
to correlate with the disease activity and it is higher in MM
patients compared to patients with monoclonal gammopathy of
undetermined significance (MGUS) suggesting that these cells can
be used as markers of disease activity and progression.65–67
Contradictory results have been published so far regarding M-
MDSC numbers and function in patients with MM. Increased
numbers of M-MDSCs have been reported in BM and PB of
newly diagnosed and relapsedMMpatients compared to patients
in remission or healthy donors suggesting their potential
consideration as prognostic predictors of disease activity68
whereas other studies have not identified such differences.63,65–
67 Discrepancies may be due to different flow-cytometric
strategies and different quantitative and qualitative character-
istics of patient cohorts.
In summary, all available evidence suggests that MDSCs are
increased in the patients with MM and participate in the
pathophysiology of the disease by inducing the survival and
proliferation of malignant plasma cells both directly and
indirectly through their immunosuppressive effects. Therefore,
MDSCs can become therapeutic targets for MM. It has been
shown that the immunomodulatory drug lenalidomide and the
proteasome inhibitor bortezomib are able to downregulate
molecules produced by MDSCs in MM; however, they cannot
abrogate the number or immunosuppressive function of
MDSCs.66 These observations emphasize the importance of
developing novel agents to overcome the immunosuppressive
effects of MDSCs in MM patients.
Immune-mediated cytopenias
Immune thrombocytopenia (ITP) is a disease entity characterized
by low platelet count due to antiplatelet autoantibodies,
abnormal effector T-cell activation and inappropriate platelet
production in the BM.69 Recent evidence suggests that MDSCs
have a role in the pathophysiology of the disease but
contradictory results have published thus far on the frequency
and function of MDSCs at diagnosis probably due to different
flow-cytometry strategies, that is, whole blood or PBMCs.70–72
Circulating MDSCs in ITP patients increase following immuno-
suppressive treatment with high dose dexamethasone (DXM) and
MDSC numbers correlate with platelet recovery suggesting that
PBMDSCs could be used as markers of response to therapy.70–72
It has also been shown that PB and splenicMDSCs in ITP patients
display impaired immunosuppressive function contributing
possibly to the pathogenesis of the disease and that DXM
(2019) 3:1 www.hemaspherejournal.com
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treatment improves the immunomodulatory properties of
MDSCs including the production of suppressive cytokines and
their T-cell suppressive effects.70 The effect of DXM on MDSCs
was found to correlate with the transcription factor Ets1 both in
ITP patients and a murine model of ITP generated following
transfer of splenocytes from CD61 knockout mice immunized
with CD61+ platelets into severe combined immunodeficient
mouse recipients.70 Interestingly, adoptive cell transfer with
MDSCs alleviated thrombocytopenia and resulted in higher
survival rate in the ITP murine model.70 Treatment with
intravenous immunoglobulin (IVIG) has been reported to
increase the number of MDSCs in spleen cell cultures from
ITP patients indicating that, in addition to blocking the
macrophage Fc receptors, IVIGmay ameliorate ITP by increasing
MDSC populations similar to DXM.73 The findings provide
novel insights linking MDSCs with the pathogenesis, disease
activity and management of ITP that need further investigation in
the clinic.
Chronic idiopathic neutropenia (CIN) is another immune-
mediated disorder characterized by prolonged, unexplained
reduction in the number of PMN associated in the majority of
patients with the presence of activated T-lymphocytes with
myelosuppressive properties that induce the apoptotic death of
the granulocytic progenitor cells.74 Preliminary data on the role
of MDSCs have shown low frequency of PB PMN-MDSCs and
M-MDSCs in CIN patients and this decrease might contribute to
the aberrant T-cell activation and sustained chronic inflammation
in CIN, a hypothesis that is currently under investigation.75
Aplastic anemia is the prototype of T-cell mediated BM failure
syndrome and the potential implication of MDSCs in the
abnormal T-cell responses associated with the disease remains an
open field for research. In a mouse model of acquired aplastic
anemia following deletion of the TGFb-activated kinase-1 gene in
hemopoietic cells, the BM failure was significantly progressed
following inactivation of TNFa signaling and was associated
with increased capacity of macrophages to prime T-helper type I
cell development and reduced ability ofMDSCs to suppress T-cell
proliferation.76
Graft versus host disease
Allo-HSCT represents the only curative treatment for a number
of hematologic malignancies. The beneficial effect of the
treatment is regularly implicated by the immunological attack
of the recipient tissues, an effect known as graft-versus-host
disease (GvHD) which is associated with significant morbidity
and mortality.77 Based on their immunesuppressive properties,
there is an increasing interest in exploring the possible implication
of MDSCs in the development of GvHD and their potential effect
on the treatment and patients’ clinical outcome.78,79 Studies have
shown that PMN-MDSCs andM-MDSCs are increased in the PB
during G-CSF stem-cell mobilization in human donors80 and that
theMDSC content of the graft correlates inversely with the risk of
acute GVHD risk in patients receiving allogeneic, G-CSF
mobilized, PB stem cells.81,82 Results from a recent study also
showed that accumulation of MDSCs in the graft and in PB
during engraftment results in successful control of severe acute
GVHD and long-term survival without any influence on the risk
of disease recurrence after allo-HSCT.83 In accordance with the
clinical data are results from murine models demonstrating that
the adoptive transfer of donorMDSCs in fullyMHC-mismatched
allo-HSCT recipients can result in successful control of GvHD
without compromising the graft versus tumor effects.84,85
Although there are no currently clinical trials using MDSC
infusions in GvHD patients, the experimental data from animal
models and observations from patients undergoing allo-HSCT
indicate that MDSCs represent a promising therapeutic tool for
the prevention and therapy of GvHD in the clinic.86 Certainly,
studies evaluating large patient cohorts and long observational
periods are required to clarify the beneficial effects of MDSCs
in patients receiving allo-HSCT versus potential risks from
infections or immunosuppression.
Discussion
In recent years, there has been an increasing interest in the
investigation of the contribution of MDSCs in the pathogenesis/
pathophysiology of hematologic diseases. Although different
protocols and strategies have been used for MDSC investigation
and characterization in hematologic diseases, there is conclusive
evidence suggesting that similar to their role in cancer induction
and progression, MDSCs have a decisive role in hematologic
malignancies by suppressing the immune reactions against the
malignant cells through previously described mechanisms10,11
(Table 1). But also, decreased number and defective function of
MDSCs may have a contributing role in the hematologic diseases
other than malignancies such as immune-mediated cytopenias
including ITP or CIN by augmenting the T-cell mediated platelet
or neutrophil destruction.70,75 Apparently, MDSCs represent
regulatory components of the immune system with critical role in
malignant and immune disorders of hemopoiesis.
A particular interest for the implication of MDSCs in
hematologic diseases originates from the fact that these cells
derive from the hemopoietic stem cells which are primarily
affected in a number of myeloid malignancies such as MDS,
MPN, and acute leukemias. AlthoughMDSCs may be part of the
malignant clone, this is not the case in all circumstances28;
definitely, however, they exert systemic immune suppressive
effects and may also contribute to a permissive BM microenvi-
ronment where the malignant cells can survive and proliferate by
evading host immune-surveillance and antitumor therapies.11 In
parallel, the malignant cells secrete cytokines, chemokines and
growth factors that may sustain and expand MDSCs in a vicious
cycle that favors the malignant cell growth and expansion. In
lymphoid malignancies, the malignant cells originate from
progenitor/precursor or mature cells of the lymphoid system;
therefore, any implication ofMDSCs in disease pathophysiology,
progression and outcome is mediated through their immune-
regulatory effects rather than the participation in the malignant
population.39–48
Apart from the current interest in exploring the reserves,
distribution and function of MDSC in hematologic diseases and
homogenization of the protocols and strategies for their study,
there is also an emerging interest in the potential of developing
novel therapeutic strategies targeting MDSCs. Interestingly, a
number of therapies currently used for hematologic malignancies
have been reported to impact on the number and function of
MDSCs and have been extensively reviewed elsewhere.10,11 For
example, all-trans retinoic acid (ATRA) has been shown to
induce the differentiation of MDSCs in mice models and patients
with solid tumors resulting in reduction of the number and the
immune-suppressive effects ofMDSCs87–90; its potential effect on
MDSCs and consequences in patients with acute promyelocytic
leukemia remains to be studied. The pyrimidine nucleoside
analog Gemcitabine has been reported to reduce the number of
MDSCs inducing therefore an antitumor immunity in mice
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models and patients with pancreatic cancer.91,92 The N-
bisphosphonate zoledronic acid has been reported to decrease
MDSCs by downregulating MMP9, among other proteins, in
patients with pancreatic cancer.93 The drug has also been shown
to inhibit the bone resorption in MM animal models by reducing
the osteoclast formation by MDSCs.62 It has also been indicated
that the anti-CD38 monoclonal antibody Daratumumab cur-
rently used for the eradication of plasma cells in MM patients
may additionally eliminate patient MDSCs which also express
CD38 according to recently reported data.94 Therefore, we may
speculate that the well-recognized beneficial effect of all the above
treatments in patients with hematologic malignancies might be
partially related to their effect on the reserves and functional
properties of MDSCs, a hypothesis that needs further investiga-
tion. On the other hand, a number of novel therapies currently
used in hematologic malignancies target pathways in tumor cells
that are also involved in the regulation of physiological processes
in MDSCs.95 Representative examples are the PI3K and Jak/Stat
signaling pathways which are therapeutic targets in lymphomas
and MPNs as well as key signaling pathways in MDSCs.95 The
possible effect of these target therapies on MDSCs and the
possibility of an additive effect on the therapeutic outcome is an
interesting field of research. It has also been shown that epigenetic
modulation of genes such as retinoblastoma 1 (Rb1) may alter the
reserves and function of MDSCs.96 It is therefore interesting to
investigate whether epigenetic regulators including the hypo-
methylating agents widely used in the treatment of MDS/AML,
have also an impact on the MDSC component of the BM
microenvironment. Even the FLT3 pathway, representing
currently a target for patients with AML and advanced systemic
mastocytosis,97 has been associated with the expansion and
function of MDSCs98; therefore the potential alterations of
MDSCs in patients treated with the FLT3 inhibitor midostaurin
remain to be investigated. Beyond the potential effect of existing
therapies on the quantitative and qualitative characteristics of
MDSCs, the development of novel therapies targeting MDSC-
related signaling pathways or surface molecules, such as CD33, is
challenging.
Despite the increasing knowledge on the biology of MDSCs, a
number of issues related to the generation, expansion, and
circulation of these cells and their precise role in the microenvi-
ronment of BM and lymphoid tissues in malignant and immune-
mediated hematologic disorders undoubtedly need further
investigation. The homogenization of the methods for MDSC
assessment is also an important issue because there is consider-
able variability in howMDSCs have been measured and reported
in different studies and the lack of uniform protocols can lead to
inconsistencies, uncertainties and erroneous conclusions.99 Even
the standard method, that is, the immunophenotyping, currently
used for the measurement of MDSCs in the low density fraction
of PBMCs and BMMCs,5 needs further improvement because it
prevents the accurate quantification of absolute MDSC numbers
whereas markers unique for MDSCs have not been identified so
far. Therefore, the functional characterization, and specifically
the T-cell suppression activity, remains a key assay for MDSC
definition (Fig. 2). Recently, guidelines for the standardization
and harmonization of the functional assays were published by a
working group from EU COST Mye-Euniter consortium (http://
www.mye-euniter.eu) aiming to diminish variations across
laboratories for the study of MDSCs from different diseases
and tissue sources.100
Overall, the better characterization of MDSCs and the



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































in MDSC generation, expansion and function are anticipated to
unravel novel pathogenetic mechanisms in normal and abnormal
hemopoiesis and may offer novel therapeutic approaches for
patients with malignant and immune-mediated hematologic
disorders including patients undergoing allo-ASCT.
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